Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder. Paediatric population Hepatobiliary disorders associated with cystic fibrosis in children aged 6 to 18 years.
For the treatment of primary biliary cirrhosis (PBC), provided there is no decompensated hepatic cirrhosis. For the dissolution of cholesterol gallstones in the gall bladder. The gallstones must not show as shadows on X-ray images and should not exceed 15 mm in diameter. The gall bladder must be functioning despite the gallstone(s). Paediatric population Hepatobiliary disorders associated with cystic fibrosis in children aged 6 to 18 years
Ursofalk 250mg/5ml Suspension is indicated in the treatment of primary biliary cholangitis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder Paediatric population Hepatobiliary disorders associated with cystic fibrosis in children aged 1 month to 18 years.
The FDA has approved Fycompa (perampanel) CIII Oral Suspension, from Eisai, as adjunctive therapy for the treatment of partial-onset seizures...
Ariad Pharmaceuticals, Inc. announced that it is temporarily suspending the marketing and commercial distribution of Iclusig (ponatinib), a treatment for...
Flexion Therapeutics, Inc.announced that the FDA approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection...
The FDA has approved AbbVie's Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with...
Neos Therapeutics, Inc. announced that the FDA has approved Adzenys ER (amphetamine) Extended-Release Oral Suspension. Neos Therapeutics is the only...
Mitsubishi Tanabe Pharma Corporation, a member of the Mitsubishi Chemical Group, announced that MTPC obtained the regulatory approval of Radicut Oral Suspension 2.1% (generic name: edaravone) for the treatment of patients with amyotrophic lateral sclerosis (ALS) from the Ministry of Health, Labour and Welfare on December 23, 2022.
Eton Pharmaceuticals, Inc., has announced the FDA has accepted for filing the company’s new drug application (NDA) for ET 104 ( zonisamide oral suspension).